Patient Inclusion Criteria

age 18-50 years; available for clinical follow-up through Week 32 of the study; able to provide proof of identity to the satisfaction of the study clinician completing the enrolment process; complete an Assessment of Understanding prior to enrolment and verbalise understanding of all questions answered incorrectly; able and willing to complete the informed consent process; willing to receive HIV test results and wiling to abide by National Institutes of Health guidelines for partner notification of positive HIV results; willing to donate blood for sample storage to be used for future research; in good general health without clinically significant medical history and has satisfactorily completed screening; physical examination and laboratory results without clinically significant findings within the 28 days prior to enrolment; laboratory criteria within 28 Days prior to enrolment: haemoglobin greater than or equal to 11.5 g/dL for women and greater than or equal to 13.5 g/dL for men, white blood cells 3,300-12,000 cells/mm3, absolute neutrophil count (ANC) within institutional normal range, total lymphocyte count greater than or equal to 800 cells/mm3, platelets within institutional normal limits, alanine aminotransferase less than or equal to upper limit of normal, serum creatinine less than or equal to upper limit of normal, normal urinalysis defined as negative glucose, negative or trace protein, and no clinically significant blood in the urine, negative FDA-approved HIV blood test, negative hepatitis B surface antigen, negative anti-HCV (hepatitis C virus antibody) and negative HCV PCR

Patient Exclusion Criteria

women who are breast-feeding or planning to become pregnant during the 32 weeks of study participation; volunteer has received any of the following substances: Immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis), blood products within 120 days prior to HIV screening, immunoglobulin within 60 days prior to HIV screening, investigational research agents within 30 days prior to initial study vaccine administration, live attenuated vaccines within 30 days prior to initial study vaccine administration, medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration, current anti-TB prophylaxis or therapy; volunteer has a history of any of the following clinically significant conditions:
serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain, autoimmune disease or immunodeficiency, asthma that is unstable or required emergent care, urgent care, hospitalisation or intubation during the past two years or that requires the use of oral or intravenous corticosteroids, diabetes mellitus (type I or II), with the exception of gestational diabetes, history of thyroidectomy or thyroid disease that required medication within the past 12 months, serious angioedema episodes within the previous 3 years or requiring medication in the previous two years, hypertension that is not well controlled by medication or is more than 145/95mm Hg at enrolment, bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws, malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study, seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years, asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen, psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrolment, any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgement of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent, allergic reaction to aminoglycoside antibiotics